Anticoagulant prescribing for atrial fibrillation and risk of incident dementia

Sharon Louise Cadogan, Emma Powell, Kevin Wing, Angel Yun Wong, Liam Smeeth, Charlotte Warren-Gash

ABSTRACT

Objective The aim of this study was to investigate the association between oral anticoagulant type (direct oral anticoagulants [DOACs] vs vitamin K antagonists [VKAs]) and incident dementia or mild cognitive impairment (MCI) among patients with newly diagnosed atrial fibrillation (AF).

Methods Using linked electronic health record (EHR) data from the Clinical Practice Research Datalink in the UK, we conducted a historical cohort study among first-time oral anticoagulant users with incident non-valvular AF diagnosed from 2012 to 2018. We compared the incidence of (1) clinically coded dementia and (2) MCI between patients prescribed VKAs and DOACs using Cox proportional hazards regression models, with age as the underlying timescale, accounting for calendar time and time on treatment, sociodemographic and lifestyle factors, clinical comorbidities and medications.

Results Of 39 200 first-time oral anticoagulant users (44.6% female, median age 76 years, IQR 68–83), 20 687 (53%) were prescribed a VKA and 18 513 (47%) a DOAC at baseline. Overall, 1 258 patients (3.2%) had GP-recorded incident dementia, incidence rate 16.5 per 1000 person-years. DOAC treatment for AF was associated with a 16% reduction in dementia diagnosis compared with VKA treatment in the whole cohort (adjusted HR 0.84, 95% CI: 0.73 to 0.98) and with a 26% reduction in incident MCI (adjusted HR 0.74, 95% CI: 0.65 to 0.84). Findings were similar across various sensitivity analyses.

Conclusions Incident EHR-recorded dementia and MCI were less common among patients prescribed DOACs for new AF compared with those prescribed VKAs.

INTRODUCTION

Atrial fibrillation (AF) is common among older people, with lifetime risk estimated at around 37% for people aged 55 years and over.1 AF is associated with adverse cardiovascular outcomes including a five-fold increase in stroke risk2 as well as incident heart failure, ischaemic heart disease and peripheral vascular disease.3 Dementia risk is approximately doubled among patients with AF4 and remains elevated by around 40% among individuals with no history of stroke. Putative mechanisms through which AF may influence dementia development are multifactorial and include ischaemic stroke or silent cerebral infarction, accumulation of microemboli, cerebral haemorrhage and systemic inflammation.5–6

Prophylactic oral anticoagulant (OAC) treatment is widely recommended to prevent stroke and systemic embolism in high-risk individuals with AF.8 A protective effect against various dementia subtypes is also plausible, given that cerebral hypoperfusion is intimately linked with neurodegeneration.9 A recent systematic review and meta-analysis of prospective studies (one RCT and five observational studies) showed a protective effect of OAC use compared with no OAC use against incident dementia in individuals with AF (RR 0.79 (95% C.I. 0.67 to 0.93)).10 Another study showed similar, though slightly attenuated, beneficial effects of OACs against a combined dementia and cognitive impairment outcome.11 For vitamin K antagonists (VKAs) such as warfarin, greater cognitive benefits were also seen with more time spent in therapeutic range. However, it was unclear whether different anticoagulant classes offered differing levels of cognitive protection. We hypothesised that direct oral anticoagulants (DOACs) such as apixaban may be more effective against incident dementia than VKAs due to better prevention of emboli, microvascular damage and strokes.12 However, existing evidence for such an effect is limited, especially among older populations with multiple comorbidities.

With the rising global burden of dementia due to population growth and ageing, and lack of effective treatments, dementia prevention is increasingly important. Understanding how, when and in whom to modify risk factors such as AF will inform dementia prevention strategies. We therefore aimed to investigate the association between DOACs or VKAs and incident dementia diagnoses in older patients newly diagnosed with AF using a longitudinal population-based cohort derived from linked primary and hospital care records from the UK.
1997. IMD data include area-based quintiles of deprivation based on patient or practice postcodes.

Study design and population
We conducted a historical cohort study among individuals with an incident diagnosis of non-valvular AF at age 40 years or more, recorded in CPRD or HES between 01 January 2012 to 31 December 2018, with at least 12 months of research-standard CPRD registration. A visual presentation of the study design is shown in online supplemental figure 1. Patients were excluded if they had a history of dementia (mild cognitive impairment (MCI) for secondary analysis) or OAC prescription prior to AF (to prevent historical recording of anticoagulant use for other reasons). Patients with AF were identified in CPRD using Read codes and in HES using ICD-10 codes.

Follow-up
Participants were followed from first OAC prescription until the earliest of: dementia diagnosis (MCI diagnosis for secondary analysis), death, transfer out of the general practice, last data collection date from the practice, end of OAC prescription or the end of study period (31 December 2018). For DOAC users, end of anticoagulant prescription was defined as last prescription date plus total days ‘on treatment’ (calculated using prescribed quantities and dosage information) plus an additional 30 days. For VKA (which has no fixed dose), we assumed that all days between two subsequent prescriptions were days on treatment, unless the gap between prescription dates exceeded 6 months or if there were no more prescriptions. In these cases, treatment was assumed to have stopped after 3 months.

Definition of exposure and outcomes
Exposure (OAC type) was defined as the first record of OAC prescription, identified using product codes in primary care records and categorized into VKAs (warfarin, phenprocoumon, acenocoumarol) and DOACs (dabigatran etexilate, apixaban, rivaroxaban). Edoxaban was not included as it was licensed in the UK at the end of 2015 and is not currently included in NICE guidance for anticoagulation in AF, so the sample size would be small. We time-updated the exposure so that individuals who switched OAC type contributed exposed time initially to one class and then to the other.

Among VKA users, we also explored the role of time in therapeutic range (TTR) as a secondary exposure. Therapeutic range was defined as having an international normalized ratio (INR) between 2 and 3. INRs carried out during the initialisation period (within 30 days of first warfarin prescription) were excluded. After setting time zero as day 31 and, using INR values from months 1 to 6, the percentage of TTR was calculated using the Rosendaal method.14 Patients were classified as having ‘good control’ (TTR >70%), ‘intermediate control’ (TTR 50%–70%) and ‘poor control’ (TTR <50%).

The primary outcome was incident all-cause dementia, defined using Read codes for first clinical diagnosis of dementia in primary care records. In sensitivity analyses, we first expanded the outcome definition to include GP-recorded administrative codes as well as clinical codes to maximize sensitivity. Second, we restricted the sample to patients with linked secondary care data, which expanded the outcome to include incident dementia recorded in GP or hospital records. Third, to reduce the risk of reverse causality, we revisited the outcome definition to include dementia occurring at least 1 year after first OAC prescription. Our secondary outcome was incident MCI, defined using clinical Read codes from primary care records.

Covariates
The following demographic and lifestyle factors were also included (using data closest to first OAC prescription, where appropriate): sex (male/female), ethnicity (Black, White, South Asian, Mixed/Other) body mass index—calculated from height and weight if available, or as entered directly, practice level IMD in quintiles (quintile 1 being the least deprived), smoking status (current/non/ex-smoker), hazardous alcohol consumption (binary; identified using Read codes) and primary care consultation frequency in the year prior to first OAC prescription. We included the following clinical conditions recorded any time prior to OAC prescription: diabetes, hypertension, myocardial infarction, heart failure, stroke/thromboembolism, vascular disease, chronic renal disease and chronic liver disease. Other potential confounders, based on previous studies, included the following medications (recorded within 1 year prior to OAC prescription): statins, antiplatelet drugs or non-steroidal anti-inflammatory drugs, angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blockers (ARB), beta-blockers, class 1 or 3 antiarrhythmics, digoxin, antipsychotics, antidepressants and proton pump inhibitors.

Codelists for all variables in the study are available on LSHTM Data Compass (DOI: https://doi.org/10.17037/DATA.00002326).

Statistical analysis
Baseline characteristics were described by anticoagulant class (VKAs vs DOACS) for first OAC prescription. We also compared characteristics of patients who switched OAC type with those who did not. Crude incidence rates of dementia were calculated overall and separately for DOACs and VKAs. We generated cumulative incidence curves using the cumulative incidence function to describe dementia incidence over time by OAC group. Cox proportional hazards regression based on the cause-specific hazard was then used to calculate HRs for dementia among DOAC versus VKAs users, with deaths from competing risks censored.15 Age was used as the underlying timescale in the models to account for strong association between age and dementia.16 Stata’s ‘stsplit’ command was used to split records at time of OAC prescription (0–6, 6–12, 12–18, 18–24, 24–36, 36–48 and 48 plus months) and calendar year. First, we adjusted for age (as the time scale), calendar year, time on treatment and sex. We then added in socioeconomic/lifestyle factors, clinical conditions and medications in blocks. Results are presented for the final model adjusting for all co-variates, using complete case analysis.

Sensitivity analyses included (1) expanding the definition of dementia to include first clinical or administrative code for dementia, (2) repeating the analyses restricted to patients with linked primary care and hospital data, (3) only including dementia outcomes that occurred at least 1 year after first OAC prescription. In a secondary analysis, we also investigated the effect of OAC type on incident MCI. Finally, we conducted further analysis of the VKA sample to explore any association between TTR and incident dementia. All analyses were performed using Stata MP V.16 (StataCorp LP).

RESULTS
The study population comprised 39,200 individuals with incident AF diagnosed from 2012 to 2018, of whom 53% (N=20,687)
were prescribed VKAs and 47% (N=18,513) DOACs at baseline, with 11% (N=4477) switching OACs during the study period (91% from VKAs to DOACs). Figure 1 shows the steps taken to identify eligible study participants and the final sample for this study.

Overall, 44.6% of the sample were female, with a median age of 76 years (IQR 68–83) and a median follow-up of 501 days (IQR 199–978). DOAC and VKA users were similar with respect to demographic and lifestyle factors, and there was no difference in the history of stroke, a major risk factor for dementia, between both groups. Nevertheless, patients prescribed VKAs generally had more comorbidities than those prescribed DOACs, particularly heart failure, other vascular disease and chronic renal disease. While patients prescribed DOACs were less likely to be using antiplatelet drugs (58.7% vs 68.7%), diuretics (43.5% vs 49.5%) and ACE inhibitors (37.8% vs 42.6%) compared with those prescribed VKAs at baseline, they had a greater use of beta-blockers (69.2% vs 66.0%), antidepressants (19.1% vs 17.7%) and proton pump inhibitors (46.7% vs 44.6%). Baseline characteristics of the sample by OAC type are shown in table 1. OAC treatment initiation patterns can be found in online supplemental figure 2. Characteristics of the 11% who switched OAC type during the study are shown in online supplemental table 1.

### Incidence rates of dementia and mild cognitive impairment

During follow-up, 1258 patients (3.2%) received a first-time diagnosis of GP-recorded dementia. The overall crude rate of all-cause dementia was 16.5 per 1000 person-years. The rate was slightly lower among patients prescribed DOACs compared with those prescribed VKAs (figure 2) and increased with age for both treatment groups (online supplemental figure 3). Overall, 1488 patients (4.0%) received a diagnosis of MCI, with a crude rate of 20.05 per 1000 person-years, which was lower among those prescribed DOACs (figure 2).
Table 1  Continued

<table>
<thead>
<tr>
<th>Conditions at baseline</th>
<th>VKA N=20687</th>
<th>DOAC N=18513</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes status</td>
<td>5538 (26.8)</td>
<td>4548 (24.6)</td>
</tr>
<tr>
<td>Hypertension history</td>
<td>14317 (69.2)</td>
<td>12403 (67.0)</td>
</tr>
<tr>
<td>Myocardial infarction history</td>
<td>2541 (12.3)</td>
<td>2071 (11.2)</td>
</tr>
<tr>
<td>Heart failure history</td>
<td>5225 (25.3)</td>
<td>3843 (20.8)</td>
</tr>
<tr>
<td>Stroke/transient ischemic attack/thromboembolism history</td>
<td>3776 (18.3)</td>
<td>3438 (18.6)</td>
</tr>
<tr>
<td>Vascular disease history</td>
<td>6002 (29.0)</td>
<td>4775 (25.8)</td>
</tr>
<tr>
<td>Renal disease history</td>
<td>6672 (32.3)</td>
<td>5235 (28.3)</td>
</tr>
<tr>
<td>Liver disease history</td>
<td>399 (1.9)</td>
<td>441 (2.4)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medications at baseline</th>
<th>VKA N=20687</th>
<th>DOAC N=18513</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statin use</td>
<td>14459 (69.9)</td>
<td>12570 (67.9)</td>
</tr>
<tr>
<td>Antiplatelet drugs/NSAIDs</td>
<td>14210 (68.7)</td>
<td>10868 (58.7)</td>
</tr>
<tr>
<td>ACE inhibitors or ARBs</td>
<td>8806 (42.6)</td>
<td>7000 (37.8)</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>13651 (66.0)</td>
<td>12815 (69.2)</td>
</tr>
<tr>
<td>Class I or III antiarrhythmics</td>
<td>1461 (7.1)</td>
<td>1065 (5.8)</td>
</tr>
<tr>
<td>Digoxin</td>
<td>2524 (12.2)</td>
<td>1914 (10.3)</td>
</tr>
<tr>
<td>Diuretics</td>
<td>10230 (49.5)</td>
<td>8045 (43.5)</td>
</tr>
<tr>
<td>Antidepressant medications</td>
<td>3667 (17.7)</td>
<td>3534 (19.1)</td>
</tr>
<tr>
<td>Antipsychotic medications</td>
<td>113 (0.5)</td>
<td>150 (0.8)</td>
</tr>
<tr>
<td>Proton pump inhibitors</td>
<td>9226 (44.6)</td>
<td>8644 (46.7)</td>
</tr>
</tbody>
</table>

ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers; BMI, body mass index; DOAC, direct oral anticoagulant; IMD, Index of Multiple Deprivation; NSAIDs, non-steroidal anti-inflammatory drugs; OAC, oral anticoagulant; VKA, vitamin K antagonist.

**DOACs versus VKAs and associations with dementia or MCI**

Treatment of AF with a DOAC was associated with a 16% reduction in incident dementia diagnosis than treatment with a VKA (HR 0.84, 95% CI: 0.74 to 0.95). Age, sex, BMI, smoking status, hypertension, myocardial infarction, statins, heart failure, stroke, vascular disease, renal disease, liver disease, antiplatelet drugs, ACE/ARB inhibitors, beta-blockers, antiarrhythmics, digoxin, diuretics, antipsychotics, antidepressants and proton pump inhibitors. DOAC, direct oral anticoagulant; VKA, vitamin K antagonist.

**Sensitivity analyses**

Sensitivity analyses are shown in table 2. Results were similar when expanding the definition of dementia to include both clinical and administrative code recorded in primary care records (N=39 028; HR 0.85, 95% CI: 0.72 to 1.01), although they just failed to reach statistical significance. A protective association was also seen when restricting the sample to patients with linked primary care and hospital records (N=18 080; HR 0.77, 95% CI: 0.60 to 0.99) and when only including dementia that occurred at least 1 year after first OAC prescription (N=39 200; HR 0.81, 95% CI: 0.67 to 0.98).

**Time in therapeutic range and incident dementia among VKA users**

Among 12 856 VKA users with at least three INRs measured in months 1–6 (median number of INRs 12, IQR 9–15), 48% (N=6186) demonstrated good control (TTR >70%), 30.3% (N=3905) intermediate control (TTR 50%–70%) and 21.7% (N=2789) poor control (TTR <50%). Good INR control was associated with 27% reduction in incident dementia diagnosis (figure 3) compared with poor INR control (HR 0.73, 95% CI: 0.57 to 0.92).

**Discussion**

In this population-based cohort study of 39 200 individuals, DOAC treatment for incident AF was associated with a 16% reduction in new diagnoses of all-cause dementia compared with treatment with VKAs. The magnitude and direction of effect estimates were consistent across sensitivity analyses. DOACs were also associated with a 26% reduction in incident MCI diagnoses.

Our results are consistent with studies suggesting favourable outcomes of DOACs compared with VKAs against composite vascular endpoints including dementia. A propensity score-matched cohort study of 5254 OAC users with AF from the USA showed that DOACs were associated with a reduction in stroke, transient ischaemic attack or dementia compared with warfarin use (HR 0.49, 95% CI 0.35 to 0.69). A large Swedish study comparing the effect of DOACs vs warfarin on ischaemic or haemorrhagic stroke or dementia among low-risk individuals suggested a protective effect of DOACs, although CIs were wide.
Valvular heart disease

Table 2  Association between oral anticoagulant use and incident dementia, in a series of sensitivity analysis

<table>
<thead>
<tr>
<th></th>
<th>No of events</th>
<th>Total person-time (person-years)</th>
<th>Crude rate (per 1000 years)</th>
<th>Adjusted for age, calendar time, time on treatment and sex</th>
<th>Fully adjusted model*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HR (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>(A) Dementia defined using clinical or administrative codes (N=39 028)*</td>
<td></td>
<td></td>
<td></td>
<td>HR (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>VKA</td>
<td>568</td>
<td>45 570</td>
<td>12.46 (11.48 to 13.53)</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>DOAC</td>
<td>353</td>
<td>32 101</td>
<td>11.00 (9.91 to 12.21)</td>
<td>0.94 (0.79 to 1.11)</td>
<td>0.46</td>
</tr>
<tr>
<td>(B) Among patients with linked GP and hospital records (N=18 080)*</td>
<td></td>
<td></td>
<td></td>
<td>HR (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>VKA</td>
<td>319</td>
<td>19 205</td>
<td>16.61 (14.88 to 18.54)</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>DOAC</td>
<td>173</td>
<td>12 907</td>
<td>13.40 (11.55 to 15.56)</td>
<td>0.84 (0.66 to 1.09)</td>
<td>0.19</td>
</tr>
<tr>
<td>(C) Dementia occurring at least 1 year after first oral anticoagulant prescription (N=39 200)*</td>
<td></td>
<td></td>
<td></td>
<td>HR (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>VKA</td>
<td>502</td>
<td>45 593</td>
<td>11.01 (10.09 to 12.02)</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>DOAC</td>
<td>234</td>
<td>32 321</td>
<td>7.23 (6.37 to 8.23)</td>
<td>0.88 (0.73 to 1.07)</td>
<td>0.20</td>
</tr>
</tbody>
</table>

*Adjusted for calendar year, time-on-treatment, sex, body mass index, smoking status, hazardous alcohol consumption, socioeconomic status (practice level IMD), primary care consultation frequency, diabetes, hypertension, myocardial infarction, statins, heart failure, stroke, vascular disease, renal disease, liver disease, antiplatelet drugs, ACE/ARB inhibitors, beta-blockers, antiarrhythmics, digoxin, diuretics, antipsychotics, antidepressants and proton pump inhibitors.
†Adjusted for same covariates as above, except for socioeconomic status—patient-level IMD used for this model.

DOAC, direct oral anticoagulant; IMD, Index of Multiple Deprivation.

(18) Although an earlier cohort study from Sweden showed no difference in dementia associated with DOACs compared with warfarin (HR 0.97, 95% CI 0.67 to 1.40), the study ended in 2014 and only 2.9% of the study population received a DOAC.19 While a recent study using UK primary care data found no significant difference in incident dementia or cognitive impairment in DOAC users versus warfarin (HR 0.89 95% CIs 0.70 to 1.14),11 as in our study, the direction of HRs favoured DOACs.

Prophylactic oral anticoagulation is recommended to prevent stroke among high-risk individuals with AF after taking bleeding risk into account.8 A systematic review and meta-analysis oftrial data showed a 19% reduction in risk of stroke or systemic embolic events among participants receiving DOACs compared with warfarin.20 Similar results were seen in a large observational study using US claims data.21 While the protective association of DOACs that we showed against diagnosed dementia was smaller than effects identified in other studies, these may have been driven by the notable effectiveness of DOACs against stroke. Mechanisms to explain the link between AF and dementia include stroke, silent cerebral infarction and microemboli, as well as indirect effects of cerebrovascular hypoperfusion on oxidative stress, inflammation and blood–brain barrier disruption, which contribute to progression of both vascular dementia and Alzheimer’s disease.22-24

Strengths and limitations

This is the first study using representative data from a real-world UK population to investigate the association between OAC type and dementia diagnosis. In contrast to other studies comparing the effect of OAC with no OAC, we used an active comparator new user design to reduce both confounding by indication and biases such as healthy user bias.30 In the UK, OACs for stroke prevention are not recommended to patients with AF aged under 65 years with low stroke risk (equating to CHA2DS2VASc score of 0 for men or 1 for women).8 We therefore did not include individuals without OACs who would have markedly lower stroke and dementia risk. In our sample, data on sociodemographic and lifestyle factors (excluding ethnicity) were >99% complete, enabling complete case analysis with negligible risk of bias. We carried out several sensitivity analyses to test the robustness of our assumptions.

There were however some limitations. While the positive predictive value of a dementia diagnosis in EHR data is over 80%,26 only two-thirds of people with dementia in the UK have their diagnosis...
The onset of dementia may lead to some individuals entering residential care. Although CPRD practices cover residential and nursing homes, some individuals may transfer to GP practices not included in CPRD for example, to be near family, which would result in missed diagnoses. As recording of dementia diagnosis may be more common among those who consult frequently, we adjusted for habitual consultation frequency. While warfarin users additionally require regular INR monitoring, all patients in our sample received regular prescriptions across the study period, so it is unlikely that dementia recording would differ by OAC type. As OAC data were obtained from prescriptions, it was not possible to assess medication adherence directly. A recent systematic review and meta-analysis suggests that one in three DOAC users has suboptimal adherence, taking their DOAC <80% of the time. In that study, pooled persistence was higher for DOACs than for VKAs. Differences in adherence may partly explain our findings: suboptimal adherence was associated with increased dementia risk among VKA users who spent <50% of time in the therapeutic range. We allowed patients switch from one OAC class to another to reduce exposure misclassification that would have occurred increasingly over time if we had based exposure on first OAC prescription. We expected minimal carryover effects: effects of DOACs fade 12–24 hours after last dose; while warfarin may stay in the system for 3–4 days after last dose. In a study of a long-term outcome such as dementia, there would be minimal effect on exposure misclassification. While switching from a VKA to a fixed dose medication may be prompted by early cognitive problems, this would bias results towards the null, bringing rates of dementia among DOAC users closer to those of VKA users. In addition, our analysis of the secondary outcome MCI, which precludes the presence of functional impairment sufficient to prevent patients from managing a variable dose VKA, showed consistent results.

In common with other studies, VKA users had evidence of slightly more comorbidities than DOAC users, although history of stroke was similar between groups, and we controlled for a wide range of measured comorbidities as potential confounders. A previous study showed that patients with extensive cardiovascular comorbidities were less likely to have a dementia diagnosis in their primary care record, despite meeting standardised diagnostic criteria. If this were also true in our study, it suggests dementia might be under-recorded in VKA users, meaning we have underestimated the protective effect of DOACs. We did not have data on some dementia risk factors, such as history of traumatic brain injury or family history of dementia, although these are unlikely to affect anticoagulant choice. In future, alternative causal inference methods such as propensity scores or marginal structural models could be explored, to control for time-varying confounding. Investigating mechanisms through which DOACs may reduce dementia risk compared with VKAs should also be a focus of future research.

Conclusions
We observed that individuals taking DOACs for AF were less likely to be diagnosed with dementia and MCI than those taking VKAs, after adjusting for potential confounding factors. While further evidence, including from randomised controlled trials, would strengthen this finding, it may be relevant to consider cognitive risk profile when prescribing OACs for AF among older individuals.

Acknowledgements
We would like to thank Professor Krishnan Bhaskaran, Professor of Statistical Epidemiology at London School of Hygiene and Tropical Medicine, for his expert statistical advice.

Key messages
What is already known on this subject?
► Oral anticoagulant use in atrial fibrillation (AF) has been linked with a reduction in dementia incidence.
► While direct oral anticoagulants (DOACs) offer superior protection against stroke and systemic embolism compared with vitamin K antagonists (VKAs) in randomised controlled trials (RCTs), it is unclear whether levels of cognitive protection differ by anticoagulant type.

What might this study add?
► We compared incident dementia diagnoses among individuals with new onset AF who were receiving either DOACs or VKAs in a large electronic health record-based cohort from the UK.
► DOAC treatment for incident AF was associated with a reduction in new diagnoses of all-cause dementia and mild cognitive impairment compared with treatment with VKAs.

How might this impact on clinical practice?
► It may be relevant to consider cognitive risk profile when prescribing oral anticoagulants for AF to older individuals.
► A better understanding of mechanisms through which anticoagulants influence dementia risk is needed, along with evidence of cognitive protection from RCTs.

Contributors CW-G, KW, LS, AYW and EP contributed to the design of the study. SLC extracted the data and performed the statistical analysis. CW-G and SLC drafted the manuscript. All authors contributed to the interpretation of the data and the review of manuscript drafts, and all approved the final manuscript.

Funding This work was supported by Wellcome (Intermediate Clinical Fellowship 201440/2/16/2 to CW-G).

Competing interests LS reports grants from Wellcome, Medical Research Council, National Institute of Health Research, Glaxo Smith Kline, the British Heart Foundation and Diabetes UK, outside the submitted work and is a Trustee of the British Heart Foundation. CW-G reports grants from Wellcome, during the conduct of the study and grants from British Heart Foundation and the Alzheimer’s Society, outside the submitted work. SLC, EP, AYW and KW have nothing to disclose.

Patient consent for publication Not required.

Ethics approval This study was approved by the Independent Scientific Advisory Committee for CPRD research (19_096) and the London School of Hygiene and Tropical Medicine ethics committee (ref: 17671).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement This study utilises data from the Clinical Practice Research Datalink, obtained under licence from the UK Medicines and healthcare products regulatory agency. The data is provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the author(s) alone. The data used in this study can only be used for the purposes set out in the submitted and approved ISAC protocol: no data can, therefore, be archived by the research team. Any future research would require a new application to CPRD with data obtained directly from CPRD, subject to their policies for scientific, data governance, and financial approvals (see www.cprd.com).

Supplemental material This content has been supplied by the author(s), it has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and the original author(s) and source are credited.
Valvular heart disease

and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Sharon Louise Cadogan http://orcid.org/0000-0002-4213-7094
Liam Smeeth http://orcid.org/0000-0002-9168-6022

REFERENCES